CI Stock Analysis: Buy, Sell, or Hold?
CI - The Cigna Group
$294.93
-5.78 (-1.92%)
▼
5d:
+3.83%
30d:
+9.79%
90d:
+2.55%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: Apr 30, 2026
0d
Smart Money Distribution
CI is up 3.8% this week, but smart money is buying puts. Top strike: $250 2026-06-18 with 4,617 OI. Put ratio: 70% View Scanner →
Strength: 3.9/10
Get Alerted When CI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CI shows positive signals but monitor for confirmation. Market pricing in 0.7% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CI shows positive signals but monitor for confirmation. Market pricing in 0.7% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$407.98
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$253.33
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CI is currently trading at $294.93, which is considered extended relative to its 30-day fair value range of $273.43 to $289.38. The stock's valuation (Forward PE: 8.8) is in line with its historical norms (8.6). At these levels, the market is pricing in 0.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CI is in a downtrend. The price is approaching resistance at $303.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $340.50 (+15.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CI is in a downtrend. The price is approaching resistance at $303.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $340.50 (+15.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$273.43 -
$289.38
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($340.50)
- NEUTRAL: Market pricing in 0.7% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$273.43 -
$289.38
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$274.01
Resistance Level
$303.33
Current Trend
Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.79
Wall Street Target
$340.50
(+15.5%)
Revenue Growth (YoY)
4.6%
Earnings Growth (YoY)
29.1%
Profit Margin
2.3%
Valuation Premium vs History
+0.7% premium
PE vs Historical
8.8 vs 8.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$296.99
(+1%)
2-Year Target
$299.07
(+1%)
3-Year Target
$301.17
(+2%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
PE COMPRESSION
$294.61
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 10.4%)
$993.62
(+237%)
Base:
(SPY PE: 8.8, Growth: 10.4%)
$396.34
(+34%)
Bear:
(PE: 7.5, Growth: 10.4%)
$336.89
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 11.85 | Current EPS (TTM): $25.38
Bull Case
$437.22
(+48%)
Analyst growth 32.2%, PE expands to 13.0
Base Case
$397.47
(+35%)
Market implied 32.2%, PE stable at 11.9
Bear Case
$204.48
(-31%)
Severe decline -20.0%, PE contracts to 10.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 14, 2026 10:48 PM ET
Data refreshes hourly during market hours. Next update: 11:48 PM
Data refreshes hourly during market hours. Next update: 11:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CI showing a specific setup today?
Insider Activity (6 Months)
5
Buys
4
Sells
+
Net
INSIDERS SELLING
Recent Transactions
Gilbert Ray Cisneros, Jr.
SELL
2026-03-13
Everett Neville
SELL
1719 shares
2026-03-02
Nicole S Jones
SELL
2307 shares
2026-03-02
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
UNH
UnitedHealth Group Incor… |
STRONG BUY
27 analysts |
$387 | 63 BUY |
|
CVS
CVS Health Corp |
STRONG BUY
28 analysts |
$100 | 55 HOLD |
|
ELV
Elevance Health Inc |
STRONG BUY
22 analysts |
$389 | 55 HOLD |
|
HUM
Humana Inc |
HOLD
26 analysts |
$244 | 57 HOLD |
|
CNC
Centene Corp |
BUY
19 analysts |
$55 | 62 BUY |
Advanced CI Option Strategies
Professional options setups generated by AI based on today's CI price and gamma walls.
